Acadian Asset Management’s Acorda Therapeutics ACOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-33,691
| Closed | -$8K | – | 2409 |
|
|
2024
Q2 | $8K | Hold |
33,691
| – | – | ﹤0.01% | 1709 |
|
|
2024
Q1 | $420K | Hold |
33,691
| – | – | ﹤0.01% | 1052 |
|
|
2023
Q4 | $489K | Hold |
33,691
| – | – | ﹤0.01% | 1034 |
|
|
2023
Q3 | $489K | Sell |
33,691
-440
| -1% | -$6.62K | ﹤0.01% | 1011 |
|
|
2023
Q2 | $442K | Sell |
34,131
-1
| -0% | -$12 | ﹤0.01% | 1083 |
|
|
2023
Q1 | $398K | Hold |
34,132
| – | – | ﹤0.01% | 1109 |
|
|
2022
Q4 | $522K | Hold |
34,132
| – | – | ﹤0.01% | 1024 |
|
|
2022
Q3 | $203K | Sell |
34,132
-2
| -0% | -$17 | ﹤0.01% | 1209 |
|
|
2022
Q2 | $318K | Buy |
34,134
+10,747
| +46% | +$191K | ﹤0.01% | 1093 |
|
|
2022
Q1 | $751K | Hold |
23,387
| – | – | ﹤0.01% | 894 |
|
|
2021
Q4 | $1.12M | Buy |
23,387
+4,267
| +22% | +$294K | ﹤0.01% | 806 |
|
|
2021
Q3 | $1.76M | Buy |
19,120
+124
| +0.7% | +$10.3K | 0.01% | 713 |
|
|
2021
Q2 | $1.81M | Hold |
18,996
| – | – | 0.01% | 735 |
|
|
2021
Q1 | $1.85M | Buy |
18,996
+1,899
| +11% | +$233K | 0.01% | 759 |
|
|
2020
Q4 | $1.42M | Buy |
17,097
+1,805
| +12% | +$166K | 0.01% | 879 |
|
|
2020
Q3 | $944K | Sell |
15,292
-225
| -1% | -$17K | ﹤0.01% | 930 |
|
|
2020
Q2 | $1.37M | Sell |
15,517
-264
| -2% | -$27.9K | 0.01% | 855 |
|
|
2020
Q1 | $1.76M | Buy |
15,781
+244
| +2% | +$48K | 0.01% | 642 |
|
|
2019
Q4 | $3.8M | Buy |
15,537
+3,337
| +27% | +$842K | 0.02% | 505 |
|
|
2019
Q3 | $4.21M | Buy |
12,200
+2,747
| +29% | +$1.49M | 0.02% | 503 |
|
|
2019
Q2 | $8.7M | Buy |
9,453
+1,761
| +23% | +$2.16M | 0.04% | 302 |
|
|
2019
Q1 | $12.3M | Buy |
7,692
+2,819
| +58% | +$5.08M | 0.05% | 259 |
|
|
2018
Q4 | $9.11M | Buy |
4,873
+1,073
| +28% | +$2.33M | 0.05% | 278 |
|
|
2018
Q3 | $8.96M | Buy |
3,800
+3,167
| +500% | +$9.8M | 0.04% | 298 |
|
|
2018
Q2 | $2.18M | Buy |
633
+111
| +21% | +$340K | 0.01% | 540 |
|
|
2018
Q1 | $1.48M | Buy |
522
+313
| +150% | +$937K | 0.01% | 648 |
|
|
2017
Q4 | $537K | Buy |
+209
| New | +$594K | ﹤0.01% | 793 |
|
|
2016
Q3 | – | Sell |
-370
| Closed | -$1.13M | – | 1585 |
|
|
2016
Q2 | $1.13M | Buy |
+370
| New | +$1.2M | 0.01% | 616 |
|
|
2014
Q3 | – | Sell |
-180
| Closed | -$728K | – | 1129 |
|
|
2014
Q2 | $728K | Buy |
+180
| New | +$734K | ﹤0.01% | 638 |
|
|
2014
Q1 | – | Sell |
-50
| Closed | -$176K | – | 1079 |
|
|
2013
Q4 | $176K | Buy |
50
+19
| +61% | +$74.1K | ﹤0.01% | 817 |
|
|
2013
Q3 | $126K | Buy |
+31
| New | +$134K | ﹤0.01% | 792 |
|
Acadian Asset Management's ACOR Position: Q3 2024 in Review
Acadian Asset Management sold out of Acorda Therapeutics (ACOR) in Q3 2024, closing a stake of 33,691 shares — an estimated $8K sold.
Acadian Asset Management first reported a position in ACOR in Q3 2013 and held it in 31 quarters. The position peaked at $12.3M in Q1 2019. 0 funds tracked by Wall St. Rank hold ACOR as of Q3 2024.
- Acadian Asset Management reported no remaining Acorda Therapeutics position as of Q3 2024 after selling out during the quarter.
- Acadian Asset Management sold 33,691 Acorda Therapeutics shares in Q3 2024, an estimated $8K.
- Acadian Asset Management first reported a position in Acorda Therapeutics in Q3 2013 and held it in 31 quarters.
- Acadian Asset Management's Acorda Therapeutics position peaked at $12.3M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2024.
Based on Acadian Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.